Any current/future new fundraising through debt or equity?

No explicit mention of any current or planned fundraising through debt or equity in the transcript provided. The company has been making significant investments via internal accruals and CAPEX, with current year CAPEX expected around Rs. 85-90 crores, possibly reaching Rs. 100 crores by year-end. Expansion and capacity additions, including pharma and printing facilities, are funded through these investments. No direct references to issuing new debt or equity for funding were discussed during the Q2 FY25 call. The focus is on capacity ramp-up, especially in pharma and IML printing, to drive fut

Any current/future capex/capital investment/strategic investment?

Current year FY25 CAPEX expected around Rs. 85-90 crores, higher than the initial Rs. 60 crores estimate due to additional printing and die-cutting machines. Pharma segment CAPEX around Rs. 34 crores this year, forming part of the overall Rs. 90-100 crores investment including pharma molds and machines. Pharma investment since last 2 years totals approximately Rs. 90 crores; total investment expected to be close to Rs. 100 crores by end of this year. FY26 CAPEX guidance tentative: expected to be around Rs. 50-60 crores, lower than current year as no greenfield projects planned; final commentar

Future growth expectations in sales/revenue/volumes?

H2 FY25 expected to be better than H1 due to all plants being operational and pharma contribution increasing from Q3-Q4. Pharma segment projected to grow significantly with Rs. 30-50 crores revenue expected in FY25 and Rs. 60 crores+ capacity potential. FY27 revenue expected to exceed Rs. 1000 crores. Paint segment volume growth expected at 12-15% from next year, improving from 7-8% this year. Qpack segment showing strong growth (around 14.53% contribution). Printing capacity to increase by 60-70% by early FY26, aiding higher sales. EBITDA margins expected to improve with better capacity utili

Future growth expectations in earnings/operating earnings/profits/EPS?

H2 expected to be better than H1 in topline due to all plants running and pharma contributions increasing from Q3 and Q4 (Rs. 3-6 crores added). EBITDA margins expected to stabilize and improve as capacity utilization increases and new printing capacities come online by Jan-April. Volume growth guidance for FY25 is double-digit, approx. 10-15%, driven by paint segment and pharma ramp-up. Pharma segment revenues targeted to grow from Rs. 30-35 crores in FY25 to up to Rs. 50-60 crores, with long-term opportunity of Rs. 100+ crores based on market penetration. EBITDA per kg aims to reach

Current/ Expected Orderbook/ Pending Orders?

Current orderbook specifics are not explicitly detailed in the transcript. Pharma segment: Several orders initiated with 6-7 companies testing products, and 3-4 already giving repeat orders. A major order was recently received from Marksans; new product development underway with possible launches from December/January. Capacity is ramping up with pharma orders expected to contribute Rs. 3 crores in Q3 and Rs. 4-6 crores in Q4. Printing capacity expansion (IML) planned to increase capacity by 60%-70% by January-April next year to support order growth. Pharma commercial supplies anticipated to s

Mold-Tek Packaging LtdQ2 FY25Industrial Products

Mold-Tek Packaging Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹659P/E: 29.3Market Cap: ₹2.2K CrSector: Industrial Products

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

H2 FY25 expected to be better than H1 due to all plants being operational and pharma contribution increasing from Q3-Q4.
Pharma segment projected to grow significantly with Rs. 30-50 crores revenue expected in FY25 and Rs. 60 crores+ capacity potential.
FY27 revenue expected to exceed Rs. 1000 crores.
Paint segment volume growth expected at 12-15% from next year, improving from 7-8% this year.
Qpack segment showing strong growth (around 14.53% contribution).
Printing capacity to increase by 60-70% by early FY26, aiding higher sales.
EBITDA margins expected to improve with better capacity utilization.
Asset turnover ratio expected to improve to around 2.5 from below 2 currently.
Pharma capacity utilization projected to reach 50%+ in FY26.
Food & FMCG segment expected to see double-digit growth once new facilities are fully operational.

Margin guidance

Category 3

H2 expected to be better than H1 in topline due to all plants running and pharma contributions increasing from Q3 and Q4 (Rs. 3-6 crores added).
EBITDA margins expected to stabilize and improve as capacity utilization increases and new printing capacities come online by Jan-April.
Volume growth guidance for FY25 is double-digit, approx. 10-15%, driven by paint segment and pharma ramp-up.
Pharma segment revenues targeted to grow from Rs. 30-35 crores in FY25 to up to Rs. 50-60 crores, with long-term opportunity of Rs. 100+ crores based on market penetration.
EBITDA per kg aims to reach Rs. 40-42 by Q1 FY26.
CAPEX for FY26 likely in Rs. 50-60 crores range, focused on expanding printing and pharma capabilities, no greenfield projects expected.
Overall optimism for continuous improvement in bottom line and potential to exceed Rs. 1000 crores revenue by FY27.

See what Mold-Tek Packaging Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

No explicit mention of any current or planned fundraising through debt or equity in the transcript provided.
The company has been making significant investments via internal accruals and CAPEX, with current year CAPEX expected around Rs. 85-90 crores, possibly reaching Rs. 100 crores by year-end.
Expansion and capacity additions, including pharma and printing facilities, are funded through these investments.
No direct references to issuing new debt or equity for funding were discussed during the Q2 FY25 call.
The focus is on capacity ramp-up, especially in pharma and IML printing, to drive future growth rather than external fundraising.

Order book

Yes

Current orderbook specifics are not explicitly detailed in the transcript.
Pharma segment: Several orders initiated with 6-7 companies testing products, and 3-4 already giving repeat orders.
A major order was recently received from Marksans; new product development underway with possible launches from December/January.
Capacity is ramping up with pharma orders expected to contribute Rs. 3 crores in Q3 and Rs. 4-6 crores in Q4.
Printing capacity expansion (IML) planned to increase capacity by 60%-70% by January-April next year to support order growth.
Pharma commercial supplies anticipated to start from Q4, with estimated pharma revenues potentially reaching Rs. 30-60 crores next financial year.
Existing clients in pharma include Marksans, MSN Labs, Graviti, Pulse, Alkem; several other pharma companies’ audits and approvals underway.
Other segments (paint, lubes) maintain ongoing orders; paint segment demand improving with capacity expansions at Panipat, Cheyyar, and Mahad plants.

See what Mold-Tek Packaging Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Current year FY25 CAPEX expected around Rs. 85-90 crores, higher than the initial Rs. 60 crores estimate due to additional printing and die-cutting machines.
Pharma segment CAPEX around Rs. 34 crores this year, forming part of the overall Rs. 90-100 crores investment including pharma molds and machines.
Pharma investment since last 2 years totals approximately Rs. 90 crores; total investment expected to be close to Rs. 100 crores by end of this year.
FY26 CAPEX guidance tentative: expected to be around Rs. 50-60 crores, lower than current year as no greenfield projects planned; final commentary closer to year-end.
Major upcoming capacity expansion includes 60-70% increase in IML printing capacity by January-February FY26, fully operational by April.
Expansion underway at Panipat, Cheyyar, and Mahad plants to meet growing demand, especially from Aditya Birla Group.

Track Mold-Tek Packaging Ltd — get its next earnings analysis in your feed

How does Mold-Tek Packaging Ltd rank vs peers in Industrial Products?

Pro feature

ThisMold-Tek Packaging Ltd

Rev 3Mar 3

See where Mold-Tek Packaging Ltd sits in Industrial ProductsSee which companies these are, and every other name in the sector.Open rankings

How does Mold-Tek Packaging Ltd rank in Industrial Products?

Compare Mold-Tek Packaging Ltd against every Industrial Products company (Q2 FY25) on revenue, margins and earnings-call signals.

View Industrial Products leaderboard →

What Mold-Tek Packaging Ltd's management said in earlier quarters

Others in Industrial Products this season

Systematic Industries Ltd (Q1 FY27)
Year-on-Year (YoY) Growth for Q4 Net Sales:** 6.0% . Key concall takeaways from Systematic Industries Ltd's Q1 FY27 earnings call — and how it ranks against…
Graphite India Ltd (Q3 FY24)
690 crore, down 1.6% y-o-y (Page 5, 9) . Key concall takeaways from Graphite India Ltd's Q3 FY24 earnings call — and how it ranks against sector peers.
Graphite India Ltd (Q4 FY24)
720 Cr, down 11.7% y-o-y (Page 4, 9) . Key concall takeaways from Graphite India Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.
Graphite India Ltd (Q4 FY25)
666 Crores, down 7.5% year-on-year (YoY) from Rs. Key concall takeaways from Graphite India Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Polycab India Ltd vs Welspun Corp Ltd vs APL Apollo Tubes

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Mold-Tek Packaging Ltd Q2 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Mold-Tek Packaging Ltd rank in Industrial Products?

Continue your research

What Mold-Tek Packaging Ltd's management said in earlier quarters

Others in Industrial Products this season